Net Health, the leading provider of software solutions for specialized outpatient care, announced today that their partnership with Osiris Therapeutics, Inc., has made Grafix®, a viable cryopreserved placental membrane, more widely available for use in acute and chronic wound treatment in outpatient wound care centers throughout the United States. Grafix is currently marketed for use as a wound allograft cover/barrier.
Net Health’s WoundExpert® EMR serves 90 percent of US outpatient wound care facilities that use specialized electronic documentation. Since implementing a full integration between Grafix and the Cell and Tissue Based Product section of WoundExpert’s Connections module, providers at these client sites can now verify patients’ insurance eligibility for Grafix in rapid time while maintaining all data and communications securely in the electronic medical record.
Increased speed of clinical documentation due to faster processing and authorization is the key advantage of this model. The insurance verification form is completed inside WoundExpert, patient data pre-populates and takes a fraction of the time providers were accustomed to when previously dealing with matters of eligibility.
Anthony Sanzo, Net Health CEO, explains his view on the benefit to their clients, “We are pleased to facilitate the ready availability of a market-leading tissue product that providers want to use—when appropriate for the patient. This model works because rapid payer approval is time saving for the staff at the facility and also accelerates initiation of the patient’s treatment.”
Osiris Vice President of Marketing, Jason Keefer, says the company is positive about the future of the relationship. “Providers want to use products that are beneficial, but time consuming coverage and reimbursement verification constraints can delay the course of treatment. This integration between Grafix and WoundExpert brings speed and transparency to the availability of Grafix on a case-by-case basis. Plus, with all related communications and documentation secured inside the WoundExpert medical record, we are streamlining a formerly cumbersome process that involved faxes, voice mail, and multi-day wait periods, and doing so in a way that ensures compliance.”
For more information on WoundExpert, visit nethealth.com/see-WoundExpert.
About Osiris Therapeutics
Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products. Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO4®, Cartiform®, Grafix®, TruSkinTM and StravixTM. Osiris, Grafix, Cartiform, TruSkin, and Stravix are trademarks of Osiris Therapeutics, Inc. BIO4® is a trademark of Howmedica Osteonics Corp. More information can be found on the company’s website, www.Osiris.com. (OSIR-G).
This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding the anticipated efficiencies and advantages of new services and the likelihood of customer adoption of new services. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.
Media Contact: Renee Vandall, 800-411-6281